Blocking certain signals during surgery to slow down ovarian cancer growth
Official title: Inhibiting beta-adrenergic and COX-2 signaling during the perioperative period to reduce ovarian cancer progression
Funded at Tel Aviv University · NIH-10937095 · Data updated 2026-11-12
This study is looking at whether certain medications can help women with ovarian cancer by reducing stress and inflammation around the time of their surgery, with the hope of improving their chances of living longer and keeping the cancer from getting worse.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tel Aviv University NIH-funded |
| Lab location | 1 site (Tel Aviv, Israel) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $136,437 |
| NIH project number | 1R21CA291683-01 |
| Project ID | NIH-10937095 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with ovarian cancer who are scheduled for surgery.
✕Less likely to help
Patients with advanced ovarian cancer who are not undergoing surgery may not benefit from this research.
What this research studies
This research investigates the effects of inhibiting beta-adrenergic and COX-2 signaling during the critical perioperative period, which is the time just before and after surgery. The study aims to explore how these interventions can reduce the growth and spread of ovarian cancer by addressing stress and inflammation that often occur during this time. By conducting a small clinical trial with women undergoing surgery for ovarian cancer, the researchers will assess the safety and effectiveness of using specific medications to potentially improve long-term survival rates and reduce cancer progression.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for slowing down ovarian cancer progression and improving survival rates for patients undergoing surgery.
How similar studies have gone: Previous small clinical trials have shown promising results with similar approaches in other types of cancer, indicating potential for success in this research.
Where this research is happening
-
Tel Aviv University
Tel Aviv, Israel Active
Researchers
- Principal investigator: Ben-Eliyahu, Shamgar — Tel Aviv University
- Study coordinator: Ben-Eliyahu, Shamgar
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.